C-CAMP has till date incubated over 30 innovative start-ups and entrepreneurs working in different areas of Life Sciences and Biotechnology. C-CAMP incubatees are currently working in the fields of drug discovery, molecular biology, transgenic model systems, biomaterials, synthetic biology, upstream & downstream processing, agricultural sciences, nutraceuticals etc.
Eyestem is creating a platform for stem cell and gene editing to develop breakthrough therapies for incurable diseases of eye. They intend to grow photoreceptors with two different approaches (cell based and organ based) and create POC for the same in animal models of retinal injury. Eyestem is working to demonstrate a repeatable process for creating retinal pigment epithelium and photoreceptors. It will also demonstrate POC in safety and efficacy for animal models of retinal injury. This work will then be taken forward to create products which have the potential to treat Acute Macular Degeneration and Retinitis Pigmentosa. More than 15 Lac patients (mostly kids) suffer from retinitis pigmentosa. If this technology can be proven to be effective and safe, it has the potential to help lacs of kids in arresting their vision loss and/or reversing their vision loss. This can have a huge impact in reducing the societal and economic burden associated with the disease.
The AVESTAGENOME Project® was conceptualized by Dr. Villoo Morawala Patell with the intent of building a complete genealogical, medical and genetic database of the Parsi population in India. The AVESTAGENOME Project™ is a systems-biology-based study of the Parsis, a genetically homogeneous community, which aims to determine the genetic basis of longevity and age-related disorders. It also aims to discover population-validated drug targets and molecular markers for diagnostics. The results of study on the Parsi population could have wide-ranging implications on human health for the general population around the world. By bringing genetic, disease and genealogical data of a population together one has already been able to locate major genes involved in some of the most common diseases, and has isolated genes in a few of these. The database generated from this project will allow multiple future uses:
- Identification of genes linked to diseases and risk prediction and planning of strategies to address prevention of diseases
- Development of diagnostic kits for early prediction of disease; development of new drug targets
- Identification of new gene therapy targets
This will be of great benefit to future generations of the Parsi community as well as humanity worldwide. While incubating at C-CAMP, AVESTAGENOME Project® will be focusing on breast cancer disease prevalent in the Parsi population.
Jiva Sciences Pvt. Ltd. is a Bengaluru based start-up and C-CAMP incubatee that takes up Research Process Outsourcing in the areas of bioengineering and point of care diagnostics. The business model is different from Contract Research Outsourcing (CRO). The design specification provided by a client is conceptualized and quickly driven for achieving road map by their multidisciplinary team. In the case of Jiva Sciences, the development will require a significant amount of original work by the company together with client collaboration. They are currently working on a microfluidic-based cell based separator for commercial applications.
NextGen Invitro Diagnostics Pvt. Ltd. is a Delhi based start-up and a C-CAMP incubatee that takes up Research Process and developed products areas of novel and point of care diagnostics. Their business model is to develop and commercialize state of the art diagnostics. They have several Indian and International collaborations for Licensing better diagnostics. They have solutions for Point Of Care and multiplexing disease diagnosis platform for Tuberculosis, Malaria and Leishmaniasis.
A young bio-energy company started by a group of graduates from IIT-Madras working on developing end-to-end solution to replace the fossil fuels.Sea6 Energy is guiding its efforts towards low-cost, large scale cultivation of red seaweed on the ocean and developing salt water based biotechnological processes to produce biofuels (ethanol, isobutanol etc.), agricultural biostimulant and phycocolloids from red seaweed. They are partly funded through the BIG as 'well as the BIPP Scheme from BIRAC and have been named the "Emerging Company of the Year" at Bangalore Bio, 2012.
A young Bangalore based start-up working on development of 'programmable' materials/ devices based on bio-inspired modules for applications in healthcare.The company was founded by and is now headed by a couple of Indian Institute of Science graduates. After winning the first prize in the BEST Scheme, they applied for and were granted the BIG scheme funding for taking their idea forward. The material they are trying to develop as a part of the BIG project is a modular elastomeric hydrogel with important applications in drug delivery and wound management amongst others.
A recent spin-off from Cellworks Research, Bugworks Research is a 4th Call BIG grantee and they are a drug discovery company that aims to discover novel treatment options for hospital acquired infections using a systems biology approach. Bugworks uses highly differentiated Systems Biology approaches to identify novel combinations that enhance the action of antibiotics and to discover novel mechanisms that target biofilms.
Biomoneta designs devices that extract and kill a wide spectrum of microbes (bacteria, fungi and viruses) from contaminated environments. Our novel decontamination technology synergistically combines the principles of electrical engineering and air-flow design with novel anti-microbial materials to achieve microbial kills of over a billion-fold.
Our primary focus is preventing the spread of infections in healthcare settings, where technological support for infection control is not widespread. Hundreds of millions of patients are affected by healthcare-associated infections (HAIs) worldwide each year, leading to significant mortality and financial losses for health systems. Nearly 30% of ICU patients succumb to infections due to poor infection control. The increasing numbers of multidrug organisms make “no-drug” solutions, such as decontamination technologies, an important part of the strategy against HAIs.
Cleanergis Biosciences is involved in Research and Development of innovative, high-quality enzymes for food and waste-water-treatment. The company is currently working on some powerful enzymes obtained through microbial sources and using algae based technologies for bioremediation of sugarcane based distillery waste. The company has developed some useful and potent Enzymes. It has adopted protein engineering solutions to get such proteins. It has a comprehensive portfolio of protein expression systems, synthetic biology methods, assay development and validation. They also offer to its clients customized solutions and proprietary technologies. Cleanergis works in partnerships with clients to ensure mutual success.
Spotsense in a resident incubate at C-CAMP. It is currently working towards creating simple affordable and accessible diagnostics especially in the field of pediatric medicine. Spittle, the first product by Spotsense is a diagnostic pacifier which has been developed as a platform for saliva based screening of various neonatal health ailments. The first offering on this platform is a rapid diagnostic test for Neonatal Sepsis. The product is currently in prototype stage and expected to be in market by 2018.
Viravecs Labs is a Bangalore based startup focusing on developing therapeutic models for drug discovery. They used cutting edge genome editing tools, engineered viruses and nanoparticles to develop transgenic cells and mouse models of various diseases. The same tools have equipped them to work on putative therapies for various genetic diseases like cancer and certain rare inherited disorders. Funded by various government grants and working with their valuable collaborators, their platform technologies have set them as the fore runners in the field of gene therapy model development in India. Viravecs Labs also caters to the academia and the industry to develop stable transgenic cell lines using CRISPR-Cas9 based genome editing and viral vectors.
Luxmatra Solutions Pvt Ltd is working on developing a novel radio-wave responsive, biodegradable nanoparticle platform for image-guided hyperthermia combined with immunotherapy for liver cancers. LuxMatra will focus on developing biodegradable nanoparticles that can trigger hyperthermic response within tumors upon exposure to low-power radio-waves.
Snaayu Lifesciences Pvt Ltd is a resident incubatee working towards isolating and characterizing novel analgesics from cone snail venom. Cone snails are venomous mollusks with around 700 species. A number of pharmacologically active peptides have been isolated from venoms of different species of cone snails. The long term goal of Snaayu Life Sciences is to use cell-based assays to target human disease pathways, particularly the nervous system, with pharmacologically active venom components to generate drug leads.
Dr. Mahesh H. B
Dr. Mahesh H. B. is an individual entrepreneur who is interested in isolating secondary metabolites from Bacillus sp. With antimicrobial activity against plant pathogens. Bacillus has been reported to have high biocontrol activity. He aims at commercializing the potential Bacillus strains and characterize the active biocontrol molecule that is stable with respect to its efficacy, production and storage.
Dr. Anand Khedkar
Dr. Anand Khedkar is a scientific leader with about 20 years of experience in biotech product development, analytics, formulation and process sciences. He has worked on oral develiery of insulin for over a dacade and made it successfully through phase 2 clinical development. He has been an inventor in multiple patents and authored several publications. His vision is to address unmet patient need through next generation peptide drugs. Towards this objective, he is working to develop a peptide editing platform to specifically deliver peptide drugs orally. Using in silico and in vitro assays, the objective will be to select novel analogues of known peptide drugs that are amenable to oral delivery, without impacting its function.
InnAccel Acceleration Services private limited is India's first medical technology acceleration company focused on innovation for low and mid-income markets. Dr. Jagdish Chaturvedi is the director of Clinical Innovation at Innaccel and leads the development of affordable medical devices for the company. He leads a team working on a technology called Noxeno, which is a novel, dedicated, easy to use device for effective removal of impacted foreign bodies (NFB) from the nasal cavity in children by GPs and/or health workers in underserved areas. Noxeno was launched recently. Another product, Sinucare - a balloon sinuplasty device for sinusitis, has also been launched.
Founded in Feb 2014, df3d is focused on developing a platform technology for healthcare solutions using 3d printed medical models and customised 3d printed surgical guides. They are based in Bangalore and are working to towards lowers costs and increasing access for 3d printing in healthcare
Coeo Labs is a young med-tech start-up focused on innovative medical devices for Emergency, Trauma and Critical Care. They have been awarded the BIG grant to take forward preliminary work performed as a part of the AIM Program (Affordable Innovation in MedTech) and develop a device for prevention of Ventilator associated pneumonia (VAP). The proposed device is an efficient secretion system that avoids pooling of secretions in the lungs which caused VAP.
Blood transfusion facility in rural area is very poor in India. There are various reasons for non-availability of blood in India, Team Bagmo is working towards addressing these issues to eradicate non availability of blood in rural India. Their first product in development is a novel blood bag monitoring solution while blood is transported to rural areas. While transporting the blood bags, cold chain should be maintained. For quality assurance temperature breaches are monitored and documented for each blood bag in their solution. This will in turn increase confidence on blood available for transfusion and also reduce unnecessary wastage of precious blood.
Dr. Kalyani Ramachandran
Dr. Kalyani Ramachandran is a molecular biologist with Ph.D. from Johns Hopkins University, USA. She is developing an affordable, point of care device for comprehensive and early detection of liver disease. Current diagnostics for detection of alcoholic and non-alcoholic liver disease are neither comprehensive nor accurate for all situations and add to increasing costs for patients. Her project will build a technology device utilizing biomarkers miRNA in blood to detect liver disease much earlier, more comprehensively and at an affordable cost bringing clarity and certainty to diagnosis. The goal is to build a point of care device for easy use, eliminating the necessity for trained personnel and laboratories. Successful adoption of the technology will transform the current market, introducing a blood based diagnostic equivalent to the gold standard biopsy.
Sensivision Health technologies Pvt LtdSensivision is a young start-up that focuses on finding innovative and affordable medical device solutions for Neonatal health challenges and is currently engaged in developing a device for treating Hypoxic Ischemic Encephalopathy, a complication of Asphyxia in Neonates. Sensivision’s solution, REVIVE, will be a comprehensive HIE management system with treatment, diagnosis and prognostication integrated on a single device. The product is currently in the final stages of prototyping.
Dr. Praveen Vemula
Dr. Vemula is an individual academician from InStem incubated at C-CAMP. His BIG-funded project involves development of a prophylactic synthetic-enzymes for prevention of chronic pesticide exposure.
Started in 2013 and based in Bangalore, Theramyt Novobiologics Pvt Ltd is a biotech company focused on biologics and biobetters. As a part of their BIG-funded project, Theramyt is developing cell line platforms which used for production of functionally improved therapeutic antibodies.
C-CAMP was incubating this BIPP funded Strand life science project a year and half back. Strand Lifesciences focuses on data mining, predictive modeling, computational chemistry, software engineering, bioinformatics, and research biology to develop software and services for life sciences research. At C-CAMP a group from Strand worked on clinical genomics and hepatotoxicity prediction platforms.
Cellworks Research India Ltd.
The wet labs for Cellworks Research India Ltd was working at C-CAMP to validate the bacterial virtual platforms that aid therapeutic product design. Cellworks is a biopharmaceutical therapeutic design and development company based on platform predicting clinical outcomes. The project was focused on building the labs abilities to identify and grade chemically vulnerable targets for anti-infectives and develop mechanism-biased drug screening assays.
Kinome Pharma Pvt Ltd is a Bangalore based venture started in November of 2013, and focused on neurodegenerative disorders. Their BIG funded project involves development of novel neuroprotective agents for Parkinson's disease. The company’s proprietary small molecule inhibitor compounds are derived from natural products.
Dr. Vinod Nayak
An individual academician from InStem, Dr. Vinod Nayak is incubating at C-CAMP and working on development of an efficient Yeast based system for membrane protein expression by designing a flexible suite of shuttle vectors with multiple promoters and affinity tags for expression and purification.
Dr. Yashoda Ghanekar
Dr. Yashoda Ghanekar is an individual academician from InStem incubated at C-CAMP. Her BIG-funded project involves establishment of invertebrate transgenic model systems through modification of lentiviral systems. The use of this technology to genetically manipulate invertebrates would make these model systems ideal for research and preliminary screenings in drug discovery and toxicology studies.
Dr. Srujan Marepally
Dr. Srujan Marepally is a lipid chemist working in developing topical/transdermal therapeutics for chronic skin inflammations such as psoriasis, ACD and eczema. Srujan is working towards the development of safer, effective and economical therapeutics from a biological source, bile salt.